WuXi Biologics, a subsidiary of WuXi PharmaTech (Cayman) Inc., began construction on a new $150 million biologics manufacturing facility in Wuxi city. The new facility, to be completed by January 2017, will be among the largest mammalian cell culture manufacturing facilities using disposable bioreactors. The added capacity will support WuXi’s biologics manufacturing pipeline in the near term.   The facility will house fourteen 2000L disposable bioreactors for fed-batch cell culture and two...